F2 and infection: Important epitopes already characterized in S1 and S2/3 within human infections, and in mouse and baboon models, suggest different inactivation strategies to blockade the receptor binding and catalytic pathways of PT, and represent potential serological correlates for next-generation vaccine development or even as biomarkers for separating infection- and vaccination-induced anti-PT antibodies.